Evaluation of the impact of pharmaceutical care for tuberculosis patients in a Secondary Referral Outpatient Clinic, Minas Gerais, Brazil.

Pharmaceutical care is a professional practice seeking the responsible provision of drug therapy by identifying, resolving, and preventing Drug-Related Problems (DRP). The study aims to describe and evaluate the impact of pharmaceutical care given to patients being treated for tuberculosis (TB). Study concurrent, longitudinal, prospective conducted during pharmaceutical care in the TB outpatient clinic, Clinical Hospital, Federal University of Minas Gerais during the period August 2009 to July 2012. The Pharmacotherapy Workup proposed by Cipolle et al. (2004) was used. Statistical analyses were performed by X2 or Fisher exact test, as appropriate. A total of 62 patients were followed up, and 128 drug-related problems (DRP) were identified: 69.5% related to safety, 13.3% to effectiveness, 12.5% ​​to indication, and 4.7% to treatment adherence, and 62.1% of the DRP were resolved. A total of 115 pharmaceutical interventions were performed. The impact of pharmaceutical care was satisfactory for 73.9% of patients with a resolution rate of 77%. There was a greater impact on pharmaceutical care (index ≥ 0.50) for those patients who were not smokers (p <0.05). The impact of pharmaceutical care was important, so the pharmacist should work alongside the multidisciplinary team to monitor treatment and perform interventions.

Evaluation of the impact of pharmaceutical care for tuberculosis patients in a Secondary Referral Outpatient Clinic, Minas Gerais, Brazil

ABSTRACT Pharmaceutical care is a professional practice seeking the responsible provision of drug therapy by identifying, resolving, and preventing Drug-Related Problems (DRP). The study aims to describe and evaluate the impact of pharmaceutical care given to patients being treated for tuberculosis (TB). Study concurrent, longitudinal, prospective conducted during pharmaceutical care in the TB outpatient clinic, Clinical Hospital, Federal University of Minas Gerais during the period August 2009 to July 2012. The Pharmacotherapy Workup proposed by Cipolle et al. (2004) was used. Statistical analyses were performed by X2 or Fisher exact test, as appropriate. A total of 62 patients were followed up, and 128 drug-related problems (DRP) were identified: 69.5% related to safety, 13.3% to effectiveness, 12.5% ​​to indication, and 4.7% to treatment adherence, and 62.1% of the DRP were resolved. A total of 115 pharmaceutical interventions were performed. The impact of pharmaceutical care was satisfactory for 73.9% of patients with a resolution rate of 77%. There was a greater impact on pharmaceutical care (index ≥ 0.50) for those patients who were not smokers (p <0.05). The impact of pharmaceutical care was important, so the pharmacist should work alongside the multidisciplinary team to monitor treatment and perform interventions.

Tratamento da tuberculose em situações especiais / Treatment of Tuberculosis in Special Settings

O objetivo deste artigo foi revisar o tratamento da tuberculose em situações especiais: pacientes com hepatopatias, nefropatias, diabetes, assim como em gestantes, nutrizes e soropositivos para o HIV. Estão relacionadas às orientações de reintrodução dos fármacos em pacientes hepatopatas, as doses ajustadas para os nefropatas, o uso de hipoglicemiantes orais e insulina em diabéticos e o uso da rifabutina em pacientes com tuberculose/HIV, além do uso da piridoxina como prevenção e tratamento de efeitos adversos. Com essas medidas, há uma melhora na qualidade de vida e no desfecho do tratamento dos pacientes com tuberculose em situações especiais

The objective of this paper was to review the treatment of tuberculosis in special settings: patients with liver disease, renal disease, or diabetes; pregnant or breastfeeding patients; and HIV-infected patients. There are guidelines related to the reintroduction of antituberculosis drugs in patients with liver disease, doses adjusted for renal disease, use of oral hypoglycemics and insulin in diabetics, and the use of rifabutin in patients with tuberculosis/HIV co-infection, as well as the use of pyridoxine to prevent and treat adverse efects. The use of the measures described can improve quality of life and treatment outcomes in patients with tuberculosis in special settings